Factor IX gene therapy - Valentis

Drug Profile

Factor IX gene therapy - Valentis

Alternative Names: Haemophilia B gene therapy - Valentis

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valentis
  • Developer Urigen Pharmaceuticals
  • Class Blood coagulation factors; Coagulants; Gene therapies
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia B

Most Recent Events

  • 25 Jan 2017 Discontinued - Preclinical for Haemophilia B in USA (IM)
  • 03 Apr 2002 Suspended - Preclinical for Haemophilia B in USA (IM)
  • 24 May 2001 Factor IX gene therapy is available for licensing (http://www.valentis.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top